NR0B1 and breast cancer: These data complement our previous findings that a single i.p. injection of EGX358 did not affect liver, heart, or kidney tissues and that EGX358 does not facilitate breast cancer cell proliferation or bind to other nuclear hormone receptors (Hanson et al., 2018).